Thus, if our in vitro cytotoxicity data correctly predicts in vivo efficacy (which has yet to be determined), only a subpopulation of lymphoma patients would have tumours suitable for treatment with internalization-dependent anti-CD19 ADCs. This evidence concerns the gene CD19 and lymphoma.